American Century Companies Inc. Sells 26,320 Shares of Twist Bioscience Corporation $TWST

American Century Companies Inc. trimmed its position in Twist Bioscience Corporation (NASDAQ:TWST) by 3.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 838,064 shares of the company’s stock after selling 26,320 shares during the quarter. American Century Companies Inc. owned 1.39% of Twist Bioscience worth $23,583,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Rafferty Asset Management LLC lifted its holdings in shares of Twist Bioscience by 51.0% during the third quarter. Rafferty Asset Management LLC now owns 114,268 shares of the company’s stock worth $3,216,000 after buying an additional 38,608 shares in the last quarter. Artisan Partners Limited Partnership increased its position in Twist Bioscience by 26.7% during the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after acquiring an additional 1,349,867 shares during the period. Fox Run Management L.L.C. bought a new position in Twist Bioscience during the third quarter worth about $440,000. Jupiter Asset Management Ltd. increased its position in Twist Bioscience by 362.2% during the third quarter. Jupiter Asset Management Ltd. now owns 245,098 shares of the company’s stock worth $6,897,000 after acquiring an additional 192,072 shares during the period. Finally, Aberdeen Group plc raised its stake in Twist Bioscience by 98.4% in the 3rd quarter. Aberdeen Group plc now owns 320,283 shares of the company’s stock worth $9,013,000 after purchasing an additional 158,879 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Evercore increased their price target on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Finally, Barclays raised their price objective on Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.88.

Twist Bioscience Price Performance

TWST stock opened at $48.33 on Tuesday. The company’s 50-day moving average price is $43.92 and its two-hundred day moving average price is $34.80. The firm has a market cap of $2.96 billion, a P/E ratio of -37.76 and a beta of 2.23. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $57.88.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The firm had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company’s revenue for the quarter was up 16.9% on a year-over-year basis. On average, analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 7,000 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $50.00, for a total transaction of $350,000.00. Following the completion of the transaction, the chief financial officer owned 130,031 shares of the company’s stock, valued at approximately $6,501,550. The trade was a 5.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jan Johannessen sold 2,200 shares of the company’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $47.91, for a total value of $105,402.00. Following the sale, the director owned 17,754 shares of the company’s stock, valued at approximately $850,594.14. This represents a 11.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 36,609 shares of company stock worth $1,665,151. 3.08% of the stock is owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.